171 related articles for article (PubMed ID: 31654334)
1. Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity.
Borrega R; Cruz JP; Taylor P; Goncalves J
BioDrugs; 2019 Dec; 33(6):693-695. PubMed ID: 31654334
[No Abstract] [Full Text] [Related]
2. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
3. [Biosimilars: assessment of efficacy, safety and cost].
Domínguez-Gil Hurlé A
Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
5. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
7. New Biosimilar Approvals for Myeloid Growth Factors and Anemia.
Lyman GH
J Natl Compr Canc Netw; 2019 May; 17(5.5):622-624. PubMed ID: 31117042
[TBL] [Abstract][Full Text] [Related]
8. Interchangeability, immunogenicity and biosimilars.
Ebbers HC; Crow SA; Vulto AG; Schellekens H
Nat Biotechnol; 2012 Dec; 30(12):1186-90. PubMed ID: 23222784
[No Abstract] [Full Text] [Related]
9. Biosimilars are coming: ready or not.
Zalcberg J
Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
[TBL] [Abstract][Full Text] [Related]
10. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
Ludwig WD; Dicheva S
Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
[TBL] [Abstract][Full Text] [Related]
11. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
12. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
13. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
14. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
Mellstedt H
Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
[TBL] [Abstract][Full Text] [Related]
15. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
16. Rumors of the Death of Biosimilars Have Been Greatly Exaggerated.
Lyman GH; Kuderer N
Cancer Invest; 2019; 37(8):325-326. PubMed ID: 31500458
[No Abstract] [Full Text] [Related]
17. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
Deiana S; Gabbani T; Annese V
World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in the Caribbean--key considerations.
Cox SD
West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
[No Abstract] [Full Text] [Related]
19. A consistency approach for evaluation of biosimilar products.
Tsou HH; Chang WJ; Hwang WS; Lai YH
J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
[TBL] [Abstract][Full Text] [Related]
20. The US Biosimilar Market: Stunted Growth and Possible Reforms.
Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
